The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V105199 | RdRP-IN-9 | 1101848-34-3 | RdRP-IN-9 (compound 6b) is a reversible covalent RdRp allosteric inhibitor. |
|
V106798 | Remdesivir intermediate-1 | 1354823-36-1 | Remdesivir intermediate-1 is a synthetic intermediate that can be used to synthesize Remdesivir. |
|
V105369 | Remdesivir methylpropyl ester analog | 3047145-80-9 | Remdesivir methyl propyl ester analog (GS-5734 methyl propyl ester analog) is a derivative of remdesivir. |
|
V53288 | Remdesivir nucleoside monophosphate | 1911578-74-9 | Remdesivir nucleoside monophosphate is the metabolite of Remdesivir. |
|
V89673 | RH12 | RH12 is a dual inhibitor of SARS-CoV-2-associated RNA-dependent RNA polymerase (RdRp, IC50 of 4.42 nM) and human transmembrane serine protease 2 (TMPRSS2, IC50 of 4.2 nM). | |
|
V81304 | Ritonavir-13C,d3 (ABT 538-13C,d3; RTV-13C,d3) | Ritonavir-13C,d3 is a 13C- and deuterated-labeled Ritonavir. | |
|
V94383 | RORγ/DHODH-IN-2 | 3000567-45-0 | RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual RORγ/DHODH inhibitor with IC50 values of 11.9 nM and 90 nM, respectively. |
|
V105110 | RU-0415529 | 1358734-35-6 | RU-0415529 is an oral SARS-CoV-2 nonstructural protein 14 (NSP14) inhibitor with IC50 of 356 nM. |
|
V106300 | S1b3inL1 | 3027437-21-1 | S1b3inL1 is a macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein. |
|
V52578 | Saquinavir-d9 (saquinavir d9) | 1356355-11-7 | Saquinavir-d9 is the deuterium labelled form of Saquinavir. |
|
V54390 | SARS-CoV MPro-IN-1 | 2413716-71-7 | SARS-CoV MPro-IN-1 is a covalent inhibitor of SARS-CoV-2 3CLpro with IC50 of 40 nM. |
|
V37556 | SARS-CoV-2 3CLpro-IN-13 | 622794-09-6 | SARS-CoV-2 3CLpro-IN-13 is a potent inhibitor of SARS-CoV-2 3CL protease with IC50 of 21 nM. |
|
V81359 | SARS-CoV-2 3CLpro-IN-14 | 2945139-50-2 | SARS-CoV-2 3CLpro-IN-14 (compound 11j) is an orally bioactive SARS-CoV-2 3CLpro inhibitor. |
|
V54421 | SARS-CoV-2 3CLpro-IN-15 | 3156-41-0 | SARS-CoV-2 3CLpro-IN-15 (compound a) is a beta-nitrostyrene coronavirus SARS-CoV-2 inhibitor that targets the SARS-CoV-2 3CL protease (3CLpro). |
|
V54402 | SARS-CoV-2 3CLpro-IN-16 | 352659-40-6 | SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). |
|
V80094 | SARS-CoV-2 3CLpro-IN-17 | SARS-CoV-2 3CLpro-IN-17 (Compound 3h) is a selective SARS-CoV-2 3CLpro inhibitor (IC50s: 0.322μM). | |
|
V81360 | SARS-CoV-2 3CLpro-IN-18 | 3032604-29-5 | SARS-CoV-2 3CLpro-IN-18 (Compound 3C) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.478 μM). |
|
V81361 | SARS-CoV-2 3CLpro-IN-19 | SARS-CoV-2 3CLpro-IN-19 (Compound C5a) is a non-covalent, non-peptide inhibitor of SARS-CoV-2 3CLpro (IC50 s: 0.7μM). | |
|
V2406 | SARS-CoV-2 3CLpro-IN-20 | 878985-00-3 | SARS-CoV-2 3CLpro-IN-20 (Compound 5g) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 0.43 μM, Ki= ?0.33μM). |
|
V80527 | SARS-CoV-2 3CLpro-IN-21 | SARS-CoV-2 3CLpro-IN-21 (Compound D6) irreversibly and covalently inhibits SARS-CoV-2 3CLpro with IC50 of 0.03μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
